RealTime Dynamix™: Psoriasis US Q3

Over the past two years, four new biologics and multiple biosimilars have been approved for the treatment of Psoriasis in the US, and dermatologists are feeling increasingly overwhelmed with the sheer number of new entrants, according to RealTime Dynamix™ Psoriasis US Q3. Click the button below to view highlights from this report: RTD: Psoriasis Q3 [...]

RealTime Dynamix™: Psoriasis US Q3 2017-09-19T16:45:45+00:00

RealTime Dynamix™: Inflammatory Bowel Disease US Q3

Remicade is considered by many as the go-to agent for treating IBD (Crohn’s disease and Ulcerative Colitis), but the introduction and adoption of TNF-inhibiting biosimilars is starting to shake up the IBD biologics market, according to RealTime Dynamix™: Inflammatory Bowel Disease US Q3, a survey of 103 US gastroenterologists fielded in August 2017. Click the [...]

RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017-09-19T16:41:00+00:00

RealTime Dynamix™: Atopic Dermatitis US Q3 2017

At roughly four months post-launch, the Dupixent (dupilumab) patient and user base has experienced substantial growth, though nearly one-third of surveyed US dermatologists (n=104) have yet to see a sales representative, according to RealTime Dynamix™ Atopic Dermatitis US Q3. Click the button below to view highlights from this report: RTD: Atopic Dermatitis Q3 Spotlight

RealTime Dynamix™: Atopic Dermatitis US Q3 2017 2017-08-29T13:31:34+00:00

Brand Focus: Betaseron in Multiple Sclerosis US 2017

Insights from the 2017 RealTime Dynamix™: Multiple Sclerosis, a quarterly series tracking the evolution of the US multiple sclerosis (MS) market, and RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis, a large-scale US patient chart audit of 1,020 MS patients who were initiated on their first-line disease-modifying therapy (DMT) in the past three months, showcase [...]

Brand Focus: Betaseron in Multiple Sclerosis US 2017 2017-08-17T16:45:13+00:00

RealTime Dynamix™: Psoriatic Arthritis US Q2 2017

In the most recent quarterly update of RealTime Dynamix™ Psoriatic Arthritis, a growing population of US rheumatologists (n=101) are reporting use of Cosentyx to treat their patients with psoriatic arthritis (PsA). Nonetheless, this increasing user base has not translated into overall increases in biologic share. Click the button below to view highlights from this quarter [...]

RealTime Dynamix™: Psoriatic Arthritis US Q2 2017 2017-08-17T16:40:32+00:00